Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-05-17
2011-05-17
Berch, Mark L (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S267000, C548S326500, C568S496000
Reexamination Certificate
active
07943625
ABSTRACT:
The present invention relates to a compound according to Formula (I)whereinR1is selected from C1-C6alkyl, and said C1-C6alkyl is substituted with C1-C6alkoxy; and at least one of said C1-C6alkyl or said C1-C6alkoxy is branched; or a pharmaceutically acceptable salt thereof, solvate or solvate of a salt thereof, as well as, to compositions containing at least one compound according to Formula (I) and methods of treating at least one disease or condition therewith.
REFERENCES:
patent: 3135753 (1964-06-01), Hitchings et al.
patent: 4657910 (1987-04-01), Morgan
patent: 4820709 (1989-04-01), Hofer
patent: 5173491 (1992-12-01), Kamoun et al.
patent: 5453426 (1995-09-01), Jacobson et al.
patent: 5489598 (1996-02-01), Connor et al.
patent: 5716967 (1998-02-01), Kleinman
patent: 5756511 (1998-05-01), West et al.
patent: 5976823 (1999-11-01), Wu
patent: 6025361 (2000-02-01), Cavalla et al.
patent: 6046019 (2000-04-01), Goumeniouk et al.
patent: 6066641 (2000-05-01), Cavalla et al.
patent: 6294541 (2001-09-01), Cavalla et al.
patent: 6319928 (2001-11-01), Chasin et al.
patent: 7108997 (2006-09-01), Kettle
patent: 7425560 (2008-09-01), Tiden
patent: 2004/0022871 (2004-02-01), Mainnemare
patent: 2004/0029871 (2004-02-01), Kettle et al.
patent: 2005/0070558 (2005-03-01), Vidal Juan et al.
patent: 2005/0234036 (2005-10-01), Hanson et al.
patent: 2007/0032468 (2007-02-01), Kettle et al.
patent: 2007/0093483 (2007-04-01), Svensson et al.
patent: 2008/0293748 (2008-11-01), Hanson et al.
patent: 2009/0054468 (2009-02-01), Eriksson et al.
patent: 2009/0131459 (2009-05-01), Tiden
patent: 2009/0149475 (2009-06-01), Tiden et al.
patent: 1013676 (1991-08-01), None
patent: 0010531 (1982-06-01), None
patent: 0359505 (1990-03-01), None
patent: 0430300 (1991-06-01), None
patent: 0452926 (1996-03-01), None
patent: 01016407 (2006-05-01), None
patent: 02160235 (1990-06-01), None
patent: 8906125 (1989-07-01), None
patent: 9500516 (1995-01-01), None
patent: 9618400 (1996-06-01), None
patent: 9914204 (1999-03-01), None
patent: 9917773 (1999-04-01), None
patent: 9936073 (1999-07-01), None
patent: 9940091 (1999-08-01), None
patent: 0051598 (2000-09-01), None
patent: 0059449 (2000-10-01), None
patent: 0185146 (2001-11-01), None
patent: 0206272 (2002-01-01), None
patent: 0208237 (2002-01-01), None
patent: 02066447 (2002-08-01), None
patent: 02090575 (2002-11-01), None
patent: 03000694 (2003-01-01), None
patent: 03082873 (2003-10-01), None
patent: 03089430 (2003-10-01), None
patent: 2004096781 (2004-11-01), None
patent: 2005037835 (2005-04-01), None
patent: 2005042534 (2005-05-01), None
patent: 2005077950 (2005-08-01), None
patent: 2006045564 (2006-05-01), None
patent: 2006046910 (2006-05-01), None
patent: 2006062465 (2006-06-01), None
Albert et al., “Reactive Chlorinating Species Produced by Myeloperoxidase Target the Vinyl Ether Bond of Plasmalogans,” J. Biol. Chem., 2001, vol. 276(26), pp. 23733-23741.
Imai et al., “Studies on Nucleic Acid Antagonists. VII. Synthesis and Characterization of 1,4,6-Triazaindenes (5H-Pyrrolo(3,2-d)pyrimidines)” Chem. Pharm. Bull., 1964, vol. 12, No. 9, pp. 1030-1042.
Kolasa et al., “Reactions of Alpha-Hydroxy Carbonyl Compounds With Azodicarboxylates and Triphenylphosphine: Synthesis of Alpha-N-Hydroxy Amino Acid Derivatives,” Journal of Organic Chemistry, 1987, vol. 52, pp. 4978-4984.
Rao et al., “Synthesis of 5,7-Disubstituted-4-Beta-D-ribofuranosylpyrazolo[4,3-d]-pyrimidines and 2,4-Disubstituted-1-Beta-D-ribofuranosylpyrrolo[3,2-d]-pyrimidines as Congeners of Uridine and Cytidine,” J. Heterocyclic Chemistry, 1992, vol. 29, pp. 343-354.
Co-Pending U.S. Appl. No. 11/577,833, filed Apr. 24, 2007.
Co-Pending U.S. Appl. No. 11/720,913, filed Jun. 5, 2007.
Aaron, S D et al., “Granulocyte Inflammatory Markers and Airway Infection during Acute Exacerbation of Chronic Obstructive Pulmonary Disease,” Am J Respir Crit Care Med., 2001, pp. 349-355, vol. 163.
Akbiyik et al., “In vitro and in vivo inhibition of myeloperoxidase with 5-fluorouracil,” Eur. J. Clin. Pharmacol., 2001, vol. 57, pp. 631-636.
Armitage et al., “Structure-Activity Relationships in a Series of 6-Thioxanthines with Bronchodilator and Coronary Dilator Properties,” British Journal of Pharmacology and Chemotherapy (1961), vol. 17, pp. 196-207.
Baldus, S. et al., “Myeloperoxidase Serum Levels Predict Risk in Patients with Acute Coronary Syndromes,” Circulation, 2003, pp. 1440-1445, vol. 108.
Berlow et al., “The Effect of Dapsone in Steroid-Dependent Asthma,” 1991, J. Allergy Clin. Immunol., 1991, vol. 87(3), pp. 710-715.
Bozeman et al., “Inhibition of the human leukocyte enzymes myeloperoxidase and eosinophil peroxidase by dapsone,” Biochemical Pharmacology, 1992, vol. 44, No. 3, pp. 553-563.
Brennan, M. et al., “Prognostic Value of Myeloperoxidase in Patients with Chest Pain,” N Engl J Med., 2003, pp. 1595-1604, vol. 349, No. 17.
Choi, D-K et al., “Ablation of the Inflammatory Enzyme Myeloperoxidase Mitigates Features of Parkinson's Disease in Mice,” J. Neurosci., 2005, pp. 6594-6600, vol. 25, No. 28.
Crooks, S W et al., “Bronchial Inflammation in Acute Bacterial Exacerbations of Chronic Bronchitis: the Role of Leukotriene B4,” European Respiratory Journal, 2000, pp. 274-280, vol. 15, No. 2.
Cuzner, M L et al., “Plasminogen Activators and Matrix Metalloproteases, Mediators of Extracellular Proteolysis in Inflammatory Demyelination of the Central Nervous System,” Journal of Neuroimmunology, 1999, pp. 1-14, vol. 94, No. 1-2.
Dallegri et al., Possible Modes of Action of Nimesulide in Controlling Neutrophilic Inflammation, Arzneimittel-Foschung/Drug Research, 1995, vol. 45(II), No. 10, pp. 1114-1117.
Daugherty, A. et al., “Myeloperoxidase, a Catalyst for Lipoprotein Oxidation, Is Expressed in Human Atherosclerotic Lesions,” J Clin Invest., 1994, pp. 437-444, vol. 94, No. 1.
Fiorini, G. et al., “Serum ECP and MPO are Increased During Exacerbations of Chronic Bronchitis with Airway Obstruction,” Biomedicine & Pharmacotherapy, 2000, pp. 274-278, vol. 54.
Garst et al., “Inhibition of Separated Forms of Phosphodiesterases from Pig Coronary Arteries by Uracils and by 7-Substituted Derivatives of 1-Methyl-3-isobutylxanthine,” J. Med. Chem.; 1976; vol. 19(4) pp. 499-503.
Green, P S et al., “Neuronal Expression of Myeloperoxidase is Increased in Alzheimer's Disease,” Journal of Neurochemistry, 2004, pp. 724-733, vol. 90, No. 3.
Grisham et al., “Assessment of Leukocye involvement during Ischemia and Reperfusion of Intestine,” Am. J. Physiol., 1986, vol. 251, pp. 729-742.
Hampton, M B, et al., “Inside the Neutrophil Phagosome: Oxidants, Myeloperoxidase, and Bacterial Killing,” Blood, 1998, pp. 3007-3017, vol. 92, No. 9.
Hope et al., “Large scale purification of myeloperoxidase from HL60 promyelocytic cells: characterization and comparison to human neutrophil myeloperoxidase,” Protein Expression and Purification, 2000, vol. 18, pp. 269-276.
Jacobson et al., “1,3-Dialkylxanthine Derivatives Having High Potency as Antagonists at Human A2B Adenosine Receptors,” Drug Development Research, 1999, vol. 47, pp. 45-53.
Katritzky et al., “A General Method for the N-Alkylation of Thioamides,” Tetrahedron Letters, (1988), vol. 29(15), pp. 1755-1758.
Kettle et al., “Assays for the Chlorination Activity of Myeloperoxidase,” Biophyl, 1992, vol. 296, pp. 502-512.
Kettle et al., “Mechanism of inhibition of myeloperoxidase by anti-inflammatory drugs,” Biochemical Pharmacology, 1991, vol. 41, No. 10, pp. 1485-1492.
Kettle et al., “Superoxide is an Antagonist of Anti-Inflammatory Drugs that Inhibit Hyposchlorous Acid Production by Myeloperoxidase,” Biochemical Pharmacology, 1993, vol. 45, No. 10, pp. 2003-2010.
Khimicheskaya encyclopedia, ed. by Knunyants I.L., “Sovetskaya encyclopedia&#x
Astrazeneca AB
Berch Mark L
LandOfFree
2 thioxanthine derivatives acting as MPO-inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 2 thioxanthine derivatives acting as MPO-inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 2 thioxanthine derivatives acting as MPO-inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2629283